Cytomegalovirus (CMV) is a member of the herpesvirus family that latently infects the majority of the population. Reactivation of latent CMV causes significant infectious complications in immunocompromised hosts, including recipients of solid organ transplants. Current anti-viral therapies are associated with toxicity and development of resistant strains. Furthermore, these therapies target replication of the virus after reactivation has occurred. The goal of this project is to better understand the molecular mechanisms that control repression of viral gene expression in latency, and to identify factors that lead to activation of viral gene expression in response to transplantation. This knowledge may lead to the development of novel therapies that prevent reactivation, rather than treating it after it has occurred. There are two overall themes: 1) that epigenetic factors control both repression of viral gene expression in latency and activation of gene expression in reactivation; 2) that an inflammatory immune response triggers reprogramming of viral chromatin to activate viral gene expression in transplant recipients.
This program project is comprised of three sub-projects and three cores. In Project 1, Dr. Abecassis will investigate molecular pathways leading to reactivation of murine CMV (MCMV) using both in vivo models that closely mimic the clinical setting of reactivation in immunocompromised transplant recipients and recently developed in vitro models. In Project 2, Dr. Hummel will investigate epigenetic factors that control latency and reactivation of HCMV in hematopoietic progenitor cells, which are sites of latency in vivo. In Project 3, Dr. Thorp will investigate MCMV infection, latency and reactivation in transplantation, specifically using donor-specific transplant tolerance.
Projects and Cores
|Faculty Associated with the Program Project: Integrating Mechanistic Insights from Diverse Models to Prevent Reactivation of CMV following Transplantation|
|PPG Program Project Director||Michael Abecassis, MD, MBA|
|Project 1 and Core C Leader||Michael Abecassis, MD, MBA|
|Project 2 Leader||Mary Hummel, PhD|
|Project 3 Leader||Edward B Thorp, PhD|
|Core A Leader||Jenny Zhang, MD|
|Core B Leader||Qing C Chen, MD, PhD|
Please join us for the 3rd Annual CMV P01 Symposium: Cytomegalovirus Latency and Reactivation
Presentations from our project core leaders
Date: Tuesday, September 25, 2018
Time: 12:00p.m. to 5:30 p.m.
Location: Prentice Harris Family Atrium – 250 E. Superior, 3rd Floor
Registration is closed.
Thank you to all who participated in our third annual CMV P01 Symposium for Cytomegalovirus Latency and Reactivation on Tuesday, September 25, 2018.
Congratulations to Dr. Michael Abecassis and colleagues for the recently awarded P01 grant issued by the National Institute of Health (NIH) titled, Integrating Mechanistic Insights from Diverse Models to Prevent Reactivation of CMV following Transplantation.